Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes-Reference-Cited by-同舟云学术

Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes

Published:2024-03-13 Issue:1 Volume:42 Page:
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Carbonell E.,Mercader C.^ORCID,Sureda J.,Gutiérrez A.,Muñoz J.,Gallardo E.,Feltes N.,Mases J.,Valduvieco I.,Vilaseca A.,Franco A.,Alcaraz A.,Musquera M.,Ribal M. J.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00345-024-04806-8.pdf

Reference29 articles.

1. Scherzer ND, DiBiase ZS, Srivastav SK et al (2019) Regional differences in the treatment of localized prostate cancer: an analysis of surgery and radiation utilization in the United States. Adv Radiat Oncol 4:331–336. https://doi.org/10.1016/j.adro.2019.01.004

2. Mahal BA, Butler S, Franco I et al (2019) Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010–2015. J Urol 202:451–452. https://doi.org/10.1001/jama.2018.19941

3. Agarwal PK, Sadetsky N, Konety BR et al (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112:307–314. https://doi.org/10.1002/cncr.23161

4. Zumsteg ZS, Spratt DE, Romesser PB et al (2015) Anatomic patterns of recurrence following biochemical relapse in the dose-escalation era for prostate patients undergoing external beam radiotherapy. J Urol 194:1624–1630. https://doi.org/10.1016/j.juro.2015.06.100.Anatomic

5. Cohen JK, Miller RJ, Ahmed S et al (2008) Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 71:515–518. https://doi.org/10.1016/j.urology.2007.09.059